US 11,738,077 B2
Immunogenic compositions comprising Lawsonia intracellularis
Jeremy Kroll, Urbandale, IA (US); and Mike Roof, Ames, IA (US)
Filed by Boehringer Ingelheim Animal Health USA Inc., Duluth, GA (US)
Filed on Oct. 12, 2020, as Appl. No. 17/68,173.
Application 15/251,308 is a division of application No. 14/477,694, filed on Sep. 4, 2014, abandoned.
Application 17/068,173 is a continuation of application No. 16/226,518, filed on Dec. 19, 2018, granted, now 10,994,004.
Application 16/226,518 is a continuation of application No. 15/251,308, filed on Aug. 30, 2016, granted, now 10,201,599, issued on Feb. 12, 2019.
Application 14/477,694 is a continuation of application No. 11/374,350, filed on Mar. 13, 2006, granted, now 8,834,891, issued on Sep. 16, 2014.
Claims priority of provisional application 60/661,352, filed on Mar. 14, 2005.
Prior Publication US 2021/0030863 A1, Feb. 4, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/02 (2006.01); A61K 39/112 (2006.01); A61K 39/12 (2006.01); C12N 7/00 (2006.01); A61K 39/39 (2006.01); A61K 35/74 (2015.01); A61K 39/295 (2006.01); A61K 39/00 (2006.01)
CPC A61K 39/105 (2013.01) [A61K 39/0241 (2013.01); A61K 39/0275 (2013.01); A61K 39/12 (2013.01); C12N 7/00 (2013.01); A61K 35/74 (2013.01); A61K 39/295 (2013.01); A61K 39/39 (2013.01); A61K 2039/521 (2013.01); A61K 2039/522 (2013.01); A61K 2039/525 (2013.01); A61K 2039/542 (2013.01); A61K 2039/55 (2013.01); A61K 2039/552 (2013.01); A61K 2039/55566 (2013.01); A61K 2039/70 (2013.01); C12N 2750/10034 (2013.01); Y02A 50/30 (2018.01); Y10S 424/825 (2013.01)] 5 Claims
 
1. A pharmaceutical composition comprising antigens which consist essentially of:
i. killed Lawsonia intracellularis bacterium,
ii. killed Mycoplasma hyopneumoniae.